AXIOS October 31, 2023
Shawna Chen

The push to use psychedelics as treatment for veterans with PTSD is gaining momentum across the country — and the Bay Area is taking the lead.

Why it matters: Studies show that MDMAs reduce PTSD symptoms and functional impairment. Advocates are working to secure FDA approval of its use in a bid to more effectively tackle the suicide epidemic among veterans.

State of play: Veterans Affairs Palo Alto is gearing up to recruit and screen participants for its own clinical trials with MDMA-assisted therapy, according to Stanford psychiatry professor Trisha Suppes, who is overseeing the research.

  • Under current protocol, patients are administered the compound three times over a 12- to 14-week period in a controlled, supervised setting with therapists.
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Patient / Consumer, Provider, VA / DoD
Wellpath sells behavioral health division for $395M
Federal mental health parity bill returns: 5 things to know
Intermountain Health Sells Its Behavioral Health Risk Model to Neuroflow
Cigna Group Foundation Grants $9 Million for Veteran Housing, Mental Stability
Jumping Jacks and Cold Water: Mental Health Tools for Kids

Share This Article